Early Results of a Phase II Study Adding Peri-Transplant Rituximab to Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients (PTS) with High-Risk Fludarabine-Refractory Chronic Lymphocytic Leukemia (Cll)

✍ Scribed by M.L. Sorror; B. Storer; B.M. Sandmaier; T. Chauncey; B. Bruno; N.N.S. Andersen; W.J. Hogan; R. Storb; D. Maloney

• Book ID: 116283309
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 93 KB
• Volume: 18
• Category: Article
• ISSN: 1083-8791
• DOI: 10.1016/j.bbmt.2011.12.505